BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 6:00 p.m. ET in San Francisco. The event will feature a presentation from the company, and a live audio webcast will be accessible on their website. BioCryst specializes in developing oral medicines for rare diseases, including its approved product ORLADEYO (berotralstat) and RAPIVAB (peramivir injection). The company is also advancing multiple therapeutic projects, including BCX10013.

RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 10, 2023, at 6:00 p.m. ET.

Links to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO^® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB^® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When will BioCryst Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

BioCryst Pharmaceuticals will present at the J.P. Morgan Healthcare Conference on January 10, 2023, at 6:00 p.m. ET.

Where can I listen to the BioCryst Pharmaceuticals presentation?

The presentation can be accessed via a live audio webcast on the BioCryst Pharmaceuticals website in the Investors & Media section.

What products does BioCryst Pharmaceuticals offer?

BioCryst Pharmaceuticals offers oral medications for rare diseases, including ORLADEYO (berotralstat) and RAPIVAB (peramivir injection).

What is the stock symbol for BioCryst Pharmaceuticals?

The stock symbol for BioCryst Pharmaceuticals is BCRX.

What is BCX10013 in relation to BioCryst Pharmaceuticals?

BCX10013 is an oral Factor D inhibitor currently in clinical development by BioCryst Pharmaceuticals.